The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure.

Journal of the American College of Cardiology
Eugene Braunwald

Abstract

The PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial demonstrated that a new angiotensin receptor antagonist-neprilysin inhibitor was superior to an angiotensin-converting enzyme inhibitor in reducing mortality in patients with heart failure and reduced ejection fraction. This paper traces the research path that culminated in the development of this drug. The first phase, elucidation of the renin-angiotensin-aldosterone system, began with Tigerstedt's discovery of renin, followed by isolation of angiotensin, isolation of angiotensin-converting enzyme, and synthesis of its inhibitors and of angiotensin receptor blockers. Phase 2 began with de Bold's discovery of atrial natriuretic peptide, followed by isolation of the enzyme that degrades it (neprilysin) and its inhibitors. Phase 3 consists of blocking both the renin-angiotensin-aldosterone and atrial natriuretic peptide-degrading systems simultaneously. A molecular complex, LCZ696, developed by scientists at Novartis, combines an angiotensin receptor blocker with a neprilysin inhibitor, is well tolerated, and represents an important step in the management of heart failure and reduced ejection fra...Continue Reading

References

Dec 1, 1978·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·A J de BoldS A Bencosme
May 4, 1978·The New England Journal of Medicine·H GavrasD N McKinstry
Jul 1, 1979·Hypertension·L S Marks, M H Maxwell
Sep 1, 1979·Proceedings of the Society for Experimental Biology and Medicine·A J De Bold
Mar 1, 1991·Journal of Cardiovascular Pharmacology·A A SeymourB Abboa-Offei
Nov 11, 1991·Hypertension·P B TimmermansA L Johnson
Aug 1, 1991·The New England Journal of Medicine·UNKNOWN SOLVD InvestigatorsJay N Cohn
Apr 30, 1990·Biochemical and Biophysical Research Communications·T SudohH Matsuo
Mar 3, 1988·Nature·T SudohH Matsuo
Jul 1, 1985·Circulation Research·J M PfefferE Braunwald
Nov 1, 1970·Proceedings of the National Academy of Sciences of the United States of America·G R MarshallP Needlemann
May 12, 1995·Journal of Medicinal Chemistry·G M KsanderA Trapani
Jul 31, 1998·The New England Journal of Medicine·E R LevinW K Samson
Sep 8, 1998·The American Journal of Physiology·O LisyJ C Burnett
Mar 27, 2001·Seikagaku. The Journal of Japanese Biochemical Society·K Takahashi
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Jan 5, 2002·The New England Journal of Medicine·J N CohnUNKNOWN Valsartan Heart Failure Trial Investigators
Mar 8, 2003·Hypertension·Duncan John Campbell
Feb 1, 1965·British Journal of Pharmacology and Chemotherapy·S H FERREIRA

❮ Previous
Next ❯

Citations

Feb 13, 2016·Journal of the American College of Cardiology·Valentin Fuster
Sep 28, 2015·Clinical Therapeutics·Peter L Thompson, Peter S Macdonald
Mar 1, 2016·Expert Review of Cardiovascular Therapy·Roberto LatiniLidia Staszewsky
Jun 24, 2015·Scandinavian Journal of Immunology·K T LappegårdA Hovland
Jul 15, 2015·JACC. Heart Failure·Monica R Shah
Aug 8, 2015·JACC. Heart Failure·Marie-France Seronde, Alexandre Mebazaa
Jul 28, 2016·Pharmacology & Therapeutics·Achim Lother, Lutz Hein
Jul 10, 2016·International Journal of Cardiology·Julio NúñezAntoni Bayés-Genís
Nov 5, 2016·Nature Reviews. Cardiology·Justin Hartupee, Douglas L Mann
Oct 18, 2016·Current Cardiology Reports·Muthiah Vaduganathan, Akshay S Desai
Nov 7, 2015·Journal of the American College of Cardiology·G William Dec
May 20, 2017·Current Treatment Options in Cardiovascular Medicine·Katie M Murphy, Julie L Rosenthal
May 18, 2017·Clinical Pharmacology and Therapeutics·M H Barghash, A S Desai
Jul 7, 2018·Cardiology in the Young·Bibhuti B DasMaryanne Chrisant
Jun 22, 2016·Circulation·Richard T Lee, Kenneth Walsh
Feb 6, 2016·Circulation Research·Anjali Tiku OwensMariell Jessup
Jan 19, 2018·Journal of Biological Engineering·Shihui FuLeiming Luo
Jun 1, 2018·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Rex C Liu
Oct 5, 2016·Clinical Medicine : Journal of the Royal College of Physicians of London·Titus W P van den HeuvelRobert Rissmann
Aug 27, 2019·Current Topics in Medicinal Chemistry·Shihui FuJuelin Deng
Sep 19, 2019·Toxicology Mechanisms and Methods·Runali SankheMadhavan Nampoothiri
Nov 19, 2015·American Journal of Therapeutics·Juan P Salazar Adum, Rohit Arora
Aug 1, 2019·The Journal of Cardiovascular Nursing·Ewa HägglundPatrik Lyngå
Mar 18, 2016·Internal and Emergency Medicine·Francesca ViazziRoberto Pontremoli
Sep 26, 2017·Basic & Clinical Pharmacology & Toxicology·Peter Munch NielsenMarcus Krüger
Jul 1, 2018·Children·Bibhuti B Das
Oct 1, 2016·Annual Review of Medicine·Anjali Tiku OwensMariell Jessup
May 16, 2018·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Inder Anand
Jul 25, 2019·International Journal of Molecular Sciences·Ryuji OkamotoMasaaki Ito
Jul 18, 2019·JACC. Basic to Translational Science·Randy T Cowling
Jan 26, 2021·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Alessandra MascarelloCristiano Ruch Werneck Guimarães
Oct 20, 2020·Annual Review of Physiology·Thomas E Sharp, David J Lefer
Jan 19, 2021·Expert Opinion on Drug Safety·Gonçalo Martins E PereiraDaniel Caldeira

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiology Journals

Discover the latest cardiology research in this collection of the top cardiology journals.

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.